Nikita Patil1, Paula D Strassle2, Sameer Arora3, Chinmay Patel4, Kishorbhai Gangani5, John P Vavalle1. 1. Division of Cardiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 2. Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 3. Center for Research and Population Health, Apex, NC, USA. 4. Department of Nephrology, Pikeville Medical Center, Pikeville, KY, USA. 5. Department of Hospital Medicine, Texas Arlington Memorial Hospital, Arlington, TX, USA.
Abstract
BACKGROUND: Atrial fibrillation (AF) is common in patients undergoing transcatheter aortic valve replacement (TAVR) but there is conflicting evidence on whether AF impacts outcomes after TAVR. METHODS: Hospitalizations of adults ≥50 years old who had undergone elective TAVR from 2012 to 2015 were included. Poisson regression was used to assess changes in in-hospital complications, average length of stay (LOS) after TAVR, and discharge disposition over time. Multivariable logistic, linear, and generalized logistic regression models, adjusting for patient and hospital characteristics, were used to estimate the effect of AF on inpatient outcomes. RESULTS: A total of 7,266 TAVR hospitalizations were included; AF was present in 44% of patients. Between 2012 and 2015, there was a significant decrease in the incidence of acute kidney injury, blood transfusion, average LOS, and inpatient mortality both for AF and non-AF patients. However, the incidences of vascular complications and major bleeding decreased only among non-AF patients. After adjustment, AF was associated with increased incidences of TIA/stroke (OR 1.36, 95% CI: 1.01, 1.85), acute kidney injury (OR 1.54, 95% CI: 1.33, 1.78), blood transfusion (OR 1.14, 95% CI: 1.00, 1.30), transfer to a skilled nursing facility (OR 1.38, 95% CI: 1.23, 1.55), and longer average LOS (CIE 1.30, 95% CI: 1.06, 1.54). AF was not associated with inpatient mortality (OR 1.09, 95% CI: 0.81, 1.48). CONCLUSIONS: AF is prevalent among patients undergoing TAVR, and is associated with higher incidences of inpatient complications, discharge to a skilled nursing facility, and longer average LOS. While the incidence of many complications has declined in the past few years, continued efforts to further reduce complications in patients with AF is urgently required for expansion of TAVR to broader populations. 2020 Cardiovascular Diagnosis and Therapy. All rights reserved.
BACKGROUND: Atrial fibrillation (AF) is common in patients undergoing transcatheter aortic valve replacement (TAVR) but there is conflicting evidence on whether AF impacts outcomes after TAVR. METHODS: Hospitalizations of adults ≥50 years old who had undergone elective TAVR from 2012 to 2015 were included. Poisson regression was used to assess changes in in-hospital complications, average length of stay (LOS) after TAVR, and discharge disposition over time. Multivariable logistic, linear, and generalized logistic regression models, adjusting for patient and hospital characteristics, were used to estimate the effect of AF on inpatient outcomes. RESULTS: A total of 7,266 TAVR hospitalizations were included; AF was present in 44% of patients. Between 2012 and 2015, there was a significant decrease in the incidence of acute kidney injury, blood transfusion, average LOS, and inpatient mortality both for AF and non-AF patients. However, the incidences of vascular complications and major bleeding decreased only among non-AF patients. After adjustment, AF was associated with increased incidences of TIA/stroke (OR 1.36, 95% CI: 1.01, 1.85), acute kidney injury (OR 1.54, 95% CI: 1.33, 1.78), blood transfusion (OR 1.14, 95% CI: 1.00, 1.30), transfer to a skilled nursing facility (OR 1.38, 95% CI: 1.23, 1.55), and longer average LOS (CIE 1.30, 95% CI: 1.06, 1.54). AF was not associated with inpatient mortality (OR 1.09, 95% CI: 0.81, 1.48). CONCLUSIONS: AF is prevalent among patients undergoing TAVR, and is associated with higher incidences of inpatient complications, discharge to a skilled nursing facility, and longer average LOS. While the incidence of many complications has declined in the past few years, continued efforts to further reduce complications in patients with AF is urgently required for expansion of TAVR to broader populations. 2020 Cardiovascular Diagnosis and Therapy. All rights reserved.
Authors: Peter Stachon; Klaus Kaier; Andreas Zirlik; Jochen Reinöhl; Timo Heidt; Wolfgang Bothe; Philip Hehn; Manfred Zehender; Christoph Bode; Constantin von Zur Mühlen Journal: Clin Res Cardiol Date: 2018-04-13 Impact factor: 5.460
Authors: David R Holmes; J Matthew Brennan; John S Rumsfeld; David Dai; Sean M O'Brien; Sreekanth Vemulapalli; Fred H Edwards; John Carroll; David Shahian; Fred Grover; E Murat Tuzcu; Eric D Peterson; Ralph G Brindis; Michael J Mack Journal: JAMA Date: 2015-03-10 Impact factor: 56.272
Authors: Giuseppe Tarantini; Marco Mojoli; Stephan Windecker; Olaf Wendler; Thierry Lefèvre; Francesco Saia; Thomas Walther; Paolo Rubino; Antonio L Bartorelli; Massimo Napodano; Augusto D'Onofrio; Gino Gerosa; Sabino Iliceto; Alec Vahanian Journal: JACC Cardiovasc Interv Date: 2016-04-13 Impact factor: 11.195
Authors: Tom Kai Ming Wang; Tharumenthiran Ramanathan; David Hyun-Min Choi; Greg Gamble; Peter Ruygrok Journal: Interact Cardiovasc Thorac Surg Date: 2014-05-05
Authors: Marina Urena; Salim Hayek; Asim N Cheema; Vicenç Serra; Ignacio J Amat-Santos; Luis Nombela-Franco; Henrique B Ribeiro; Ricardo Allende; Jean-Michel Paradis; Eric Dumont; Vinod H Thourani; Vasilis Babaliaros; Jaume Francisco Pascual; Carlos Cortés; Bruno García Del Blanco; François Philippon; Stamatios Lerakis; Josep Rodés-Cabau Journal: Circulation Date: 2014-12-02 Impact factor: 29.690